enoxacin has been researched along with Respiratory Tract Infections in 12 studies
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.
enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.
Respiratory Tract Infections: Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this open, non-comparative study 45 lower respiratory tract infections were treated with the new 4-quinolone, enoxacin." | 7.67 | Enoxacin in lower respiratory tract infections. ( van Griethuysen, AJ; van Herwaarden, CL; Van Klingeren, B; Vree, TB; Wijnands, WJ, 1986) |
| " Hence when these 2 agents are given concurrently, careful monitoring of theophylline concentrations and/or dosage adjustments are recommended." | 6.38 | Tissue penetration and clinical efficacy of enoxacin in respiratory tract infections. ( Wood, MJ, 1989) |
| "In this open, non-comparative study 45 lower respiratory tract infections were treated with the new 4-quinolone, enoxacin." | 3.67 | Enoxacin in lower respiratory tract infections. ( van Griethuysen, AJ; van Herwaarden, CL; Van Klingeren, B; Vree, TB; Wijnands, WJ, 1986) |
| " Hence when these 2 agents are given concurrently, careful monitoring of theophylline concentrations and/or dosage adjustments are recommended." | 2.38 | Tissue penetration and clinical efficacy of enoxacin in respiratory tract infections. ( Wood, MJ, 1989) |
| "Against respiratory tract infections with K." | 1.28 | In vivo evaluation of NM441, a new thiazeto-quinoline derivative. ( Kimura, K; Kise, M; Kitano, M; Matsuda, M; Nishino, T; Otsuki, M; Ozaki, M; Segawa, J; Shibata, K; Tomii, Y, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (75.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grassi, C | 1 |
| Mangiarotti, P | 1 |
| Dal Prà, ML | 1 |
| Hara, K | 1 |
| Saito, A | 1 |
| Izumikawa, K | 1 |
| Yamaguchi, K | 1 |
| Suzuyama, Y | 1 |
| Shigeno, Y | 1 |
| Watanabe, K | 1 |
| Komori, M | 1 |
| Yamashita, K | 1 |
| Miyazaki, Y | 1 |
| Cherubin, CE | 1 |
| Eng, RH | 1 |
| Smith, SM | 1 |
| Tan, EN | 1 |
| Ozaki, M | 1 |
| Matsuda, M | 1 |
| Tomii, Y | 1 |
| Kimura, K | 1 |
| Segawa, J | 1 |
| Kitano, M | 1 |
| Kise, M | 1 |
| Shibata, K | 1 |
| Otsuki, M | 1 |
| Nishino, T | 1 |
| Zhang, YY | 1 |
| Zhun, BY | 1 |
| Jiang, SC | 1 |
| Wood, MJ | 1 |
| Piddock, LJ | 1 |
| Wijnands, WJ | 3 |
| Wise, R | 1 |
| Neu, HC | 1 |
| Vree, TB | 2 |
| Van Herwaarden, CL | 2 |
| van Griethuysen, AJ | 1 |
| Van Klingeren, B | 1 |
| Davies, BI | 1 |
| Maesen, FP | 1 |
| Joet, FP | 1 |
| Nourrit, J | 1 |
| Frances, Y | 1 |
| Arnaud, A | 1 |
1 review available for enoxacin and Respiratory Tract Infections
| Article | Year |
|---|---|
Tissue penetration and clinical efficacy of enoxacin in respiratory tract infections.
Topics: Animals; Enoxacin; Humans; Respiratory Tract Infections | 1989 |
2 trials available for enoxacin and Respiratory Tract Infections
| Article | Year |
|---|---|
[Comparative clinical study of enoxacin (AT-2266, ENX) and cefaclor (CCL) in chronic respiratory tract infections by a double-blind method].
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Cefaclor; Cephalexin; Chronic Disease; Clinical Trials | 1984 |
[Clinical evaluation of enoxacin].
Topics: Adult; Dysentery, Bacillary; Enoxacin; Female; Gram-Negative Bacterial Infections; Humans; Male; Mid | 1991 |
9 other studies available for enoxacin and Respiratory Tract Infections
| Article | Year |
|---|---|
Enoxacin: clinical results in lower respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Bacterial Infections; C | 1989 |
A comparison of antimicrobial activity of ofloxacin, L-ofloxacin, and other oral agents for respiratory pathogens.
Topics: Administration, Oral; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Cefuroxime; Ciprof | 1992 |
In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dogs; Drug Evaluati | 1991 |
Quinolone/ureidopenicillin cross-resistance.
Topics: Adult; Bacterial Outer Membrane Proteins; Drug Resistance, Microbial; Enoxacin; Humans; Male; Naphth | 1987 |
Clinical use of the quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Enoxacin; Gastrointestinal Diseases; Humans; Naphthy | 1987 |
The effect of the 4-quinolone enoxacin on plasma theophylline concentrations.
Topics: Adult; Aged; Anti-Infective Agents; Drug Interactions; Enoxacin; Female; Half-Life; Humans; Male; Mi | 1986 |
Enoxacin in lower respiratory tract infections.
Topics: Adult; Aged; Enoxacin; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Naphthyridine | 1986 |
Clinical efficacy of the new quinolones in lower respiratory infections.
Topics: Aged; Anti-Infective Agents; Bacteria; Ciprofloxacin; Enoxacin; Humans; Microbial Sensitivity Tests; | 1987 |
Enoxacin in the treatment of bronchopulmonary infections.
Topics: Anti-Infective Agents; Enoxacin; Female; Humans; Male; Middle Aged; Naphthyridines; Respiratory Trac | 1985 |